Framework 4 minute read · May 10, 2026

The 1/10/100 Principle: What a $1 Idea Actually Costs

Generating an idea costs a dollar. Developing it costs ten. Commercializing it costs a hundred. Less than 10% of a venture's lifetime capital is deployed before the scale decision. Most ventures fail after the hundred is already spent.

The most expensive failure pattern in corporate innovation does not start with a bad idea. It starts with a good idea that was never subjected to an honest structural read before the capital committed.

The 1/10/100 principle captures why. The numbers are relative, not literal — but the pattern is real, and the gap between where most organizations apply diagnostic rigor and where the decision actually matters is consistently in the same place.

The Principle

Generating an idea costs a dollar. The whiteboard session, the strategy offsite, the innovation week where teams pitch concepts — these are cheap relative to what comes next.

Developing the idea into a product costs ten. The MVP build, the pilot program, the initial customer validation, the product team — an order of magnitude more expensive than the idea itself.

Commercializing the product at scale costs a hundred. The go-to-market buildout, the sales infrastructure, the marketing spend, the ongoing operations — an order of magnitude more again. And if the venture is creating a new category rather than entering an existing one, closer to two hundred.

Most ventures do not fail at the one-dollar stage. They fail at the hundred-dollar stage — after the organization has committed the staffing, the budget, and the political will that makes pivoting nearly impossible.

Where the Capital Actually Goes

In most corporate venturing portfolios, less than 10% of total lifetime venture capital is deployed in the ideation and hypothesis stages combined — the work that sets the direction for everything that follows. The remaining 90% is deployed in Stage 2 proving, Stage 3 go-to-market buildout, and Stage 4 scaling and integration.

<10%

Typical share of total lifetime venture capital deployed at Stage 0–1, where the direction for the remaining 90% is set. In a $10M venture exposure, this represents $400K–$700K — the window where structured diagnosis is both most valuable and most underused.

That early slice is where the direction is set. The 90% executes it. And the problem is not that organizations underspend at Stage 1 — it is that they underspend on structured diagnosis at Stage 1. Workshops and ideation sessions, yes. A rigorous external assessment of whether the organizational host can actually execute what the venture requires — almost never.

So the hypothesis is never honestly stress-tested. The structural misalignment is never named. The capital commits to Stage 3 anyway. By the time the Stage 3 spend is locked in, the structural verdict that should have been issued at Stage 1 is now the post-mortem.

What a Structured Gate at Stage 1 Costs

The Venture Architecture Diagnostic is a low-five-figure gate inserted at Stage 1 — before a potential $3–4M Stage 3 commitment locks in. At a total venture exposure of $10M, the VAD fee represents less than 1% of total lifetime capital.

If the diagnostic produces a GO verdict, the Stage 3 commitment proceeds with a 20–30 page evidence base, a bias-calibrated financial model, and a named validation experiment playbook. The capital commits to something that has been externally stress-tested.

If it produces a PIVOT verdict, the Stage 3 commitment is restructured around the pivot — saving the cost of building the wrong product at full commercial scale before the market surfaces the mismatch.

If it produces a WRONG COMPANY verdict, the Stage 3 commitment is redirected toward a partnership, a licensing arrangement, or a different host — capturing the value of the idea without absorbing the organizational cost of forcing an incompatible host to execute it.

If it produces a NO-GO verdict, the Stage 3 commitment is avoided entirely. The capital returns to the portfolio rather than confirming, at three times the cost, what the Stage 1 diagnostic already showed.

The Pattern Library Confirms the Pattern

At N=128 in the THC Pattern Library, the median time between when a structural signal was detectable and when the organization acted on it was 24 months. The signal that would have been visible at Day 4 of a structured sprint took two years to reach the defunding decision.

The one-dollar stage is not just the cheapest place to answer the question. It is the earliest place the question can be honestly asked — before capital commitment makes honest answers politically costly.

Take the 5-Question RPP Readiness Check

Five minutes. A directional read on whether your organizational host is structurally positioned to execute what your venture requires. No scoring language. No verdict. The question that tells you whether you need one.

Take the Check →

The most expensive question in corporate innovation deserves a structured answer.

Book a 30-minute discovery call. No pitch. A direct conversation about your venture and whether the VAD is the right next step.